Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN) (IMPOCNPIC)

12 november 2026 uppdaterad av: Centre Hospitalier Intercommunal Creteil

Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN): A Descriptive Study of Occupational Issues to Guide Occupational Therapy Intervention

Advances in cancer treatment have increased the number of patients living with long-term treatment-related consequences. Among these, chemotherapy-induced peripheral neuropathy (CIPN) is common and can significantly affect patients' quality of life and daily activities. Despite its impact, CIPN remains difficult to manage, and patients often receive insufficient support regarding its functional and occupational consequences.

Occupational therapy remains underutilised in oncology, despite its potential to help patients maintain or regain independence in meaningful daily activities. Collaboration between Advanced Practice Nurses and occupational therapists could improve the identification and management of occupational difficulties associated with CIPN.

The aim of this study is to describe the occupations affected by CIPN using the Canadian Occupational Performance Measure (COPM). The findings will help identify patients' occupational needs and guide future occupational therapy interventions.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

In 2023, 433,136 new cancer cases were reported in France, accounting for 8.1 million hospital admissions. Thanks to advances in cancer treatment, the number of patients living with long-term consequences of cancer or its treatment is steadily increasing.

Cancer control policies in France have been based on successive Cancer Plans, followed by the adoption of the 2021-2030 Ten-Year Cancer Control Strategy. This strategy is structured around four priority areas, including the second: "Reducing long-term consequences and improving quality of life." Indeed, two out of three people experience lasting effects five years after a cancer diagnosis. This priority aims to promote research to reduce long-term consequences and improve patients' quality of life, as well as to prevent, detect and manage the effects associated with the disease and its treatments. In particular, findings from the VICAN 5 study show that 63.5% of cancer survivors continue to experience disease- or treatment-related consequences five years after diagnosis. Among these patients, 35.3% reported neuropathic pain, which negatively affects their quality of life and daily activities. Chemotherapy-induced peripheral neuropathy (CIPN) is common and remains difficult to manage because of its limited response to pharmacological treatments.

Current literature highlights a lack of support and care for patients experiencing CIPN, as well as insufficient knowledge regarding its impact on their daily activities and occupations.

The cancer care pathway can be divided into three main stages: diagnosis disclosure, treatment, and post-cancer care. Advanced Practice Nurses (APNs) can intervene at different stages of this pathway. They play a major role in long-term follow-up, particularly in identifying and monitoring treatment-related side effects and long-term consequences. However, their role, which primarily focuses on screening and monitoring, does not allow them to provide specific interventions aimed at improving the management of CIPN-related difficulties.

Occupational therapy aims to help individuals regain or maintain their independence in carrying out everyday activities. It offers a wide range of interventions but remains underutilised in oncology, for several reasons, including limited awareness of the profession, insufficient knowledge of its potential benefits, and difficulties accessing occupational therapy services.

In the management of CIPN, collaboration between Advanced Practice Nurses and occupational therapists could help establish effective care pathways, combine their respective expertise and promote patients' engagement in activities affected by CIPN.

The objective of this study is to describe the occupations (activities or groups of activities performed regularly and considered meaningful and valuable by individuals) affected by CIPN, using the Canadian Occupational Performance Measure (COPM).

Occupational performance is defined as an individual's ability to perform meaningful occupations adequately, efficiently and to their own satisfaction.

Studietyp

Observationell

Inskrivning (Beräknad)

50

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adult patients with chemotherapy-induced peripheral neuropathy, grade 2 or 3 according to CTCAE: caused by paclitaxel in cases of breast cancer or by oxaliplatin in cases of colorectal cancer.

Patients must be able to carry on a conversation in French.

Beskrivning

Inclusion Criteria:

  • Patient treated for breast cancer or colorectal cancer, who has not previously received paclitaxel or oxaliplatin.
  • Patient with grade 2 or 3 peripheral neuropathy, according to the CTCAE criteria, occurring during their treatment.
  • Patient able to communicate in French.
  • Patient aged 18 years or older

Exclusion Criteria:

  • History of neuropathy prior to treatment.
  • Refusal to participate in the study.
  • Protected persons (pregnant or breastfeeding women, individuals under guardianship or curatorship, minors, individuals deprived of their liberty, or individuals unable to provide informed consent).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiv: PROSPECTIVE

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Description of the occupational issues identified as priorities by patients
Tidsram: 3 months

Describe the occupational issues identified as priorities by patients based on the categories and subcategories of occupations defined by the MCRO

3 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient verbatim
Tidsram: 3 months

Patient verbatim statements regarding their priority occupational issues, grouped according to the MCRO categories and subcategories

3 months
Performance and satisfaction scores
Tidsram: 3 months

Performance and satisfaction scores obtained across each category and subcategory of the MCRO

3 months
Number and percentages of priority problematic occupations
Tidsram: 3 months

Number and percentages of priority problematic occupations, coded according to the categories and subcategories of the MCRO, based on the two types of treatment received.

3 months
Number and percentages of priority adverse events
Tidsram: 3 months

Number and percentages of priority adverse events, coded according to the categories and subcategories of the MCRO, based on the two CTCAE grading scales

3 months
Average time to onset of NPICs by treatment received
Tidsram: 3 months

Average time to onset of NPICs by treatment received. The time to onset of NPICs is defined as the interval (in days) between the start date of treatment and the date of NPIC diagnosis

3 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 november 2026

Primärt slutförande (Beräknad)

9 februari 2027

Avslutad studie (Beräknad)

9 februari 2027

Studieregistreringsdatum

Först inskickad

12 november 2026

Först inskickad som uppfyllde QC-kriterierna

12 november 2026

Första postat (Faktisk)

19 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera